drugset / Trial / NCT06757894
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Phase 2
Not yet recruiting
50 enrolled
Sun Yat-sen University
Fifth Affiliated Hospital of Guangzhou Medical University · collabFifth Affiliated Hospital, Sun Yat-Sen University · collabGansu Cancer Hospital · collabGanzhou Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2028-02-01
- Completion
- 2034-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | — |
| Subject | Zuberitamab | Monoclonal antibody | 375 mg/m2 | — |